Physician profile
Ty C Smith
NPI 1811769599
$1,477.86
in general payments reported to CMS, 2019-2025
23 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $980 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $193.56 | 2024 | Farxiga, Wainua, Andexxa |
| Novartis Pharmaceuticals Corporation | $166.51 | 2024-2025 | |
| Atricure, INC. | $141.44 | 2025 | Synergy Ablation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.79 | 2024-2025 | Lifevest |
| Dilon Technologies, INC. | $93.71 | 2025 | Hemoblast Bellows |
| Peerless Surgical INC. | $92.72 | 2025 | |
| Merck Sharp & Dohme LLC | $90.77 | 2024-2025 | Verquvo, Zerbaxa |
| Philips North America LLC | $83.76 | 2024 | (5091) Amb Mon & Diag Und |
| Boston Scientific Corporation | $73.39 | 2024-2025 | Watchman Flx |
| Irhythm Technologies, INC. | $68.50 | 2024 | Zio Monitor, Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.72 | 2024 | Jardiance |
| Abiomed | $48.55 | 2024 | Impella |
| Novo Nordisk INC | $44.38 | 2024 | Wegovy |
| Edwards Lifesciences Corporation | $35.12 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Getinge USA Sales, LLC | $22.99 | 2025 | Vasoview Hemopro 2 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.74 | 2024 | |
| Solventum Corporation | $19.75 | 2025 | Prevena |
| Amgen INC. | $19.49 | 2024 | Repatha |
| Cardiva Medical, INC. | $18.82 | 2024 | Savvywire |
| Lexicon Pharmaceuticals, INC. | $16.49 | 2024 | |
| Pfizer INC. | $15.48 | 2024 | |
| Octapharma USA, INC. | $14.89 | 2025 | Fibryga |
| Cvrx, INC. | $14.29 | 2024-2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ty Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.